Evaluation of Asarum europaeum L. Rhizome for the Biological Activities Related to Alzheimer’s Disease

Document Type: Original paper

Authors

1 Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran.

2 Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran.

3 School of Pharmacy, International Campus (TUMS-IC), Tehran University of Medical Sciences, Tehran, Iran.

4 Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

5 Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran.Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

6 Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran.Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.Faculty of Land and Food Systems, University of British Columbia, Vancouver, BC, Canada.

Abstract

Background and objectives: Asarum europaeum L. is an herbal medicine belonging to the family Aristolochiaceae. The rhizome of the plant has been used for the treatment of various diseases in complementary and alternative medicine of various countries. In Iranian traditional medicine (ITM), the aqueous extract of the rhizome has been used for the improvement and enhancement of memory. Methods: In the present study, the aqueous and hydroalcoholic extracts as well as different fractions of A. europaeum rhizome were evaluated for their cholinesterase (ChE), acetyl- and butyrylcholinesterase (AChE and BChE) inhibitory activity viamodified Ellman's method.  Results: The ethyl acetate fraction selectively showed the most suitable anti-AChE activity (IC50 = 99.69 µg/mL); none of the extracts or fractions demonstrated anti-BChE activity. In this regard, the ethyl acetate fraction was candidate for the investigation of further biological activities such as antioxidant activity, neuroprotectivity, and metal chelating ability related to Alzheimer’s disease. It depicted favorable neuroprotectivity at concentration of 100 μg/mL against the toxicity of exposure to H2O2 in PC12 cells (p£0.001, cell viability = 80/60%) and chelating ability towards zinc, iron, and copper ions. The results of antioxidant activity by DPPH assay showed that the ethyl acetate fraction was much more potent than BHA as the reference drug. Conclusion: The ethyl acetate fraction ofA. europaeum L. showed potent biological activities involved in Alzheimer’s disease and needs complementary investigations to develop an herbal product against Alzheimer’s disease.

Keywords

Main Subjects


[1] Sharma K. Cholinesterase inhibitors as Alzheimer's therapeutics. Mol Med Rep. 2019; 20(2): 1479-1487.
[2] Naseri NN, Wang H, Guo J, Sharma M, Luo W. The complexity of tau in Alzheimer’s disease. Neurosci Lett. 2019; 705: 183-194.
[3] Sikanyika NL, Parkington HC, Smith AI, Kuruppu S. Powering amyloid beta degrading enzymes: a possible therapy for Alzheimer’s disease. Neurochem Res. 2019; 44(6): 1289-1296.
[4] Iraji A, Khoshneviszadeh M, Firuzi O, Khoshneviszadeh M, Edraki M. Novel small molecule therapeutic agents for Alzheimer disease: focusing on BACE1 and multi-target directed ligands. Bioorg Chem. 2020; Article ID 103649.
[5] Liu Y, Nguyen M, Robert A, Meunier B. Metal ions in Alzheimer’s disease: a key role or not? Acc Chem Res. 2019; 52(7): 2026-2035.
[6] Simmons EC, Scholpa NE, Schnellmann RG. Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases. Exp Neurol. 2020; Artice ID 113309.
[7] Kirson NY, Meadows ES, Desai U, Smith BP, Cheung HC, Zuckerman P, Matthews BR. Temporal and geographic variation in the incidence of Alzheimer's disease diagnosis in the US between 2007 and 2014. J Am Geriatr Soc. 2020; 68(2): 346-353.
[8] Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs. 2017; 26(6): 735-739.
[9] Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020; 27(1): 1-13.
[10] Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008; 3(2): 211-225.
[11] Sameem B, Saeedi M, Mahdavi M, Shafiee A. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease. Eur J Med Chem. 2017; 128: 332-345.
[12] Mullane K, Williams M. Alzheimer’s disease (AD) therapeutics-1: repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochem Pharmacol. 2018; 158: 359-375.
[13] Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement. 2019; 5: 272-293.
[14] Koynova R, Tenchov B. Natural product formulations for the prevention and treatment of Alzheimer's disease: a patent review. Recent Pat Drug Deliv Formul. 2018; 12(1): 23-29.
[15] Howes MJR, Perry E.  The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging. 2011; 28(6): 439-468.
[16] Tundis R, Bonesi M, Menichini F, Loizzo M. Recent knowledge on medicinal plants as source of cholinesterase inhibitors for the treatment of dementia. Mini Rev Med Chem. 2016; 16(8): 605-618.
[17] Saeedi M, Babaie K, Karimpour-Razkenari E, Vazirian M, Akbarzadeh T, Khanavi M, Hajimahmoodi M, Shams Ardekani MR. In vitro cholinesterase inhibitory activity of some plants used in Iranian traditional medicine. Nat Prod Res. 2017; 31(22): 2690-2694.
[18] Eftekhari M, Ardekani MRS, Amin M, Attar F, Akbarzadeh T, Safavi M, Karimpour-razkenari E, Amini M, Isman M, Khanavi M. Oliveria decumbens, a bioactive essential oil: chemical composition and biological activities. Iran J Pharm Res. 2019; 18(1): 412-421.
[19] Dos Santos TC, Gomes TM, Pinto BAS, Camara AL, Paes AMA. Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer's disease therapy. Front Pharmacol. 2018; Article ID 1192.
[20] Kopyt’ko YF, Shchurevich NN, Sokol’skaya TA, Markaryan AA, Dargaeva TD. Uses, chemical composition, and standardization of plant raw material and medicinal substances from plants of the genus Asarum L. Pharm Chem J. 2013; 47(3): 157-168.
[21] Azam Khan HM. The greatest elixir (Exir Azam). Tehran: Research Institute for Islamic and Complementary Medicine, 2009.
[22] Zargari A. Medicinal plants. Vol 4. Tehran: Tehran University Press, 1996.
[23] Momen Tonekaboni SM. Tohfatol-momenin. Tehran: Shahr Publications, 2007.
[24] Khorasani MA. Makhzan-al-advieh. Tehran: Institute of Medical History, Islamic Medicine and Complementary Medicine, Iran Medical University, 2001.
[25] IbnSina H. Al-qanun fi'l-tibb. 6th ed.  Tehran: Surush, 1991.
[26] Usta C, Yildirim AB, Turker AU. Antibacterial and antitumour activities of some plants grown in Turkey. Biotechnol Biotechnol Equip. 2014; 28(2): 306-315.
[27] Saifuddin MK, Gopalakrishna CH, Dattatraya VK, Kamalhasan BS, Suresh DK, Pankaj JL. Gastroprotective and antiulcer activity of mixture of Symplocos racemosa bark and Asarum europaeum root. J Pharm Res. 2010; 3(7): 1502-1505.
[28] Adhami HR, Farsam H, Krenn L. Screening of medicinal plants from Iranian traditional medicine for acetylcholinesterase inhibition. Phytother Res. 2011; 25(8): 1148-1152.
[29] Kahkeshani N, Hadjiakhoondi A, Navidpour L, Akbarzadeh T, Safavi M, Karimpour-Razkenari E, Khanavi M. Chemodiversity of Nepeta menthoides Boiss. & Bohse. essential oil from Iran and antimicrobial, acetylcholinesterase inhibitory and cytotoxic properties of 1,8-cineole chemotype. Nat Prod Res. 2018; 32(22): 2745-2748.
[30] Golfakhrabadi F, Yousefbeyk F, Mirnezami T, Laghaei P, Hajimahmoodi M, Khanavi M. Antioxidant and antiacetylcholinesterase activity of Teucrium hyrcanicum. Pharmacogn Res. 2015; 7(S1): 15.
[31] Mahdavi M, Hariri R, Mirfazli SS, Lotfian H, Rastergari A, Firuzi O, Edraki N, Larijani B, Akbarzadeh T, Saeedi M. Synthesis and biological activity of some Benzochromenoquinolinones: Tacrine analogs as potent anti‐Alzheimer's agents. Chem Biodivers. 2019; Article ID e1800488.
[32] Rastegari A, Nadri H, Mahdavi M, Moradi A, Mirfazli SS, Edraki N, Moghadam FH, Larijani B, Akbarzadeh T, Saeedi M. Design, synthesis and anti-Alzheimer’s activity of novel 1, 2, 3-triazole-chromenone carboxamide derivatives. Bioorg Chem. 2019; 83: 391-401.
[33] Rahmani-Nezhad S, Dianat S, Mahdizadeh V, Fooladi Z, Hariri R, Najafi Z, Firuzi O, Vahedi-Mazdabadi Y, Farjadmand F, Akbarzadeh T, Saeedi M, Ardekani MS. Investigation of polysaccharide extracts from Iranian and French strains of Agaricus subrufescens against enzymes involved in Alzheimer’s disease. B Latinoam Caribe P L. 2019; 18(6): 544-554.
[34] Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with β-amyloid deposits in Alzheimer’s disease. J Struct Biol. 2006; 155(1): 30-37.
[35] Guilloreau L, Combalbert S, Sournia‐Saquet A, Mazarguil H, Faller P. Redox chemistry of copper–amyloid‐β: The generation of hydroxyl radical in the presence of ascorbate is linked to redox‐potentials and aggregation state. Chem Bio Chem. 2007; 8(11): 1317-1325.
[36] Nunan J, Small DH. Regulation of APP cleavage by α‐, β‐and γ‐secretases. FEBS Lett. 2000; 483(1): 6-10.
[37] Singh YP, Pandey A, Vishwakarma S, Modi G. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases. Mol Divers. 2019; 23(2): 509-526.
[38] Uddin MS, Al Mamun A, Kabir MT, Jakaria M, Mathew B, Barreto GE, Ashraf GM. Nootropic and anti-Alzheimer’s actions of medicinal plants: molecular insight into therapeutic potential to alleviate Alzheimer’s neuropathology. Mol Neurobiol. 2019; 56(7): 4925-4944.
[39] Limón ID, Mendieta L, Díaz A, Chamorro G, Espinosa B, Zenteno E, Guevara J. Neuroprotective effect of alpha-asarone on spatial memory and nitric oxide levels in rats injected with amyloid-β (25–35). Neurosci Lett. 2009; 453(2): 98-103.
[40] Kim BW, Koppula S, Kumar H, Park JY, Kim IW, More SV, Kim IS, Han SD, Kim SK, Yoon SH, Choi DK. α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease. Neuropharmacology. 2015; 97: 46-57.
[41] Pages N, Maurois P, Delplanque B, Bac P, Stables JP, Tamariz J, Chamorro G, Vamecq J. Activities of α-asarone in various animal seizure models and in biochemical assays might be essentially accounted for by antioxidant properties. Neurosci Res. 2010; 68(4): 337-344.
[42] Li C, Xing G, Dong M, Zhou L, Li J, Wang G, Zou D, Wang R, Liu J, Niu Y. Beta-asarone protection against beta-amyloid-induced neurotoxicity in PC12 cells via JNK signaling and modulation of Bcl-2 family proteins. Eur J Pharmacol. 2010; 635(1): 96-102.
[43] Li Z, Zhao G, Qian S, Yang Z, Chen X, Chen J, Cai C, Liang X, Guo J. Cerebrovascular protection of β-asarone in Alzheimer's disease rats: a behavioral, cerebral blood flow, biochemical and genic study. J Ethnopharmacol. 2012; 144(2): 305-312.
[44] Zou DJ, Wang G, Liu JC, Dong MX, Li XM, Zhang C, Zhou L, Wang R, Niu YC. Beta-asarone attenuates beta-amyloid-induced apoptosis through the inhibition of the activation of apoptosis signal-regulating kinase 1 in SH-SY5Y cells. Pharmazie. 2011; 66(1): 44-51.
[45] Belova LF, Alibekov SD, Baginskaia AI, Sokolov SIa, Pokrovskaia GV. Asarone and its biological properties. Farmakol Toksikol. 1985; 48(6):17-20.